Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Status:
Completed
Trial end date:
2019-06-06
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see whether the combination of selinexor (KPT-330) can
help people with triple negative breast cancer (TNBC). Researchers also want to study the
safety and tolerability of Selinexor in TNBC patients.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute